ORKAOruka Therapeutics, Inc.

Healthcare
$82.17+428% 1Y

The financials

Oruka Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 9, 2026, a quarter after the last one.

Oruka Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$50M−$28Mn/a
Net income−$41M−$25Mn/a
Diluted EPSn/a−$0.46n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #182 of 196 by RyuScore

Compare peers
CAI+7.9%
Caris Life Sciences, Inc.
CRSP+5.9%
CRISPR Therapeutics AG
DNTH-0.05%
Dianthus Therapeutics, Inc.
MANE+3.0%
Veradermics, Incorporated
XENE+0.75%
Xenon Pharmaceuticals Inc.
TVTX+0.14%
Travere Therapeutics, Inc.